期刊文献+

TPF方案联合放疗治疗口腔鳞癌的临床疗效及毒副反应观察 被引量:3

Clinical Study of TPF regimen followed by radiotherapy in the Treatment of Advanced oral squamous cell carcinoma
暂未订购
导出
摘要 目的:观察TPF方案[多烯紫杉醇(TXT)+顺铂(CDDP)+氟尿嘧啶(5-FU)]联合放疗治疗晚期口腔鳞癌的疗效和毒副反应。方法:对48例晚期口腔鳞癌患者应用TPF方案进行治疗,其中TXT 70mg/m2,静脉滴入,d1给药;DDP 30mg/m2,静脉冲入,d1-3给药,5-FU 500-750mg/m2,静脉滴入,d1-5给药,21-28天为1周期,每例治疗2-3个周期后,给予总量为68.4Gy的常规放射治疗,具体为:每天1.8or2Gy,每周5天。结果:48例患者中总有效率(RR)为85.4(41/48),其中CR31.3(15/48),PR54.2%(26/48),SD12.5%(6/48),PD2.1%(1/48),中位生存期8.9个月(4-24个月),主要毒副反应为骨髓抑制及消化道反应。结论:TPF方案联合放疗治疗口腔鳞癌疗效确切,毒副反应可以耐受。 Objective:To evaluate the efficiency and toxicity of TPF regimen chemotherapy(Docetaxel+Cisplatin + fluorouracil) in the treatment of oral squamous cell carcinoma.Methods:Forty-eight patients were treated with TPF regimen,TXT 70mg/m2,ivdrip,d1 and d8;DDP 30mg/m2,iv,from d1 to d3,5-FU 500-750mg/m2 ivdrip from d1 to d5.The therapy was repeated every 21-28 days.Results:The overall response rate was 85.4(41 /48),with CR 31.25(15 /48),PR 54.16%(26/48),SD12.5%(6/48),and PD 2.08%(1/48).The median overall survival of the whole group was 8.7 months(2-24 months).The major toxicity and side effects were myelosuppression,nausea and vomiting.Conclusion:TPF regimen is effective for the advanced oral squamous cell carcinoma and the toxicity and side effects are tolerable.
出处 《现代肿瘤医学》 CAS 2010年第12期2358-2360,共3页 Journal of Modern Oncology
关键词 TPF方案 化放疗 多烯紫杉醇 顺铂 氟尿嘧啶 口腔鳞癌 TPF regimen chemoradiotherapy docetaxel cisplatin fluorouracil oral squamous cell carcinoma
  • 相关文献

参考文献12

  • 1Eich HT,Loschcke M,Scheer M,et al.Neoadjuvant radiochemotherapy and radical resection for advanced squamous cell carcinoma of the oral cavity.Outcome of 134 patients[J].Strahlenther Onkol,2008,184(1):23.
  • 2Lam L,Logan RM,Luke C,Rees GL.Retrospective study of survival and treatment pattern in a cohort of patients with oral and oropharyngeal tongue cancers from 1987 to 2004[J].Oral Oncol,2007,43(2):150-158.
  • 3Preuss SF,Dinh V,Klussmann JP,et al.Outcome of ultimodal treatment for oropharyngeal carcinoma:a single institution experience[J].Oral Oncol,2007,43(4):402-407.
  • 4Calais G,Pointreau Y,Alfonsi M,et al.Garaud P (2006) Journal of Clinical Oncology,2006 ASCO annual meeting proceedings part I[J].June 20 Supplement,2006,5506.
  • 5Osner MR,Hershock DM,Blajman CR,et al.Cisplatin and Xuorouracil alone or with docetaxel in head and neck cancer[J].N Engl J Med 25;357(17):1705-1715.
  • 6刘流,赵德萍,谢春,陆信,李坚,漆雪梅,陈锡玲.化疗药物对头颈癌敏感性的研究[J].口腔颌面外科杂志,2001,11(3):204-207. 被引量:8
  • 7Hitt R,López-Pousa A,Martínez-Trufero J,et al.Phase III study comparing cisplatin plus Xuorouracil to paclitaxel,cisplatin,and Xuorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer[J].J Clin Oncol,2005,23:8636-8645.
  • 8Hitt R,Paz-Ares L,Brandáriz A,et al.Induction chemotherapy with paclitaxel,cisplatin and 5-Xuorouracil for squamous cell carcinoma of the head and neck:long-term results of a phase II trial[J].Ann Oncol,2003,13:1665-1673.
  • 9Catimel G,Verweij J,Mattijssen V,et alDocetaxel (Taxotere):an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck.EORTC Early Clinical Trials Group[J].Ann Oncol,1994,5:533-537.
  • 10Vermorken JB,Remenar E,van Herpen C,et al.Cisplatin,Xuorouracil,and docetaxel in unresectable head and neck cancer[J].N Engl J Med,2007,357:1695-1704.

二级参考文献2

  • 1[1]Woo MH, Relling MV, Sonnichsen DS. Phase 1 targeted systemic exposure study of paclitaxel in children with refractory acute leukemias[J].J Clin Cancer Res, 1999, 5(3): 543
  • 2韩晓凤,王燕婷,欧阳仁荣.MTT法体外药敏试验研究进展[J].肿瘤,1999,19(1):55-58. 被引量:33

共引文献12

同被引文献24

  • 1刘三霞,胡敏,陶冶,王家志,陈丽洁,刘华蔚,罗金超.重组人p53腺病毒注射液联合放疗治疗口腔鳞癌的近期疗效观察[J].中华临床医师杂志(电子版),2011,5(22):6590-6593. 被引量:2
  • 2陈智伟,廖美琳.RECIST标准在肿瘤治疗疗效评价中的应用[J].中国肿瘤,2004,13(10):616-618. 被引量:185
  • 3尹明平,费伟,李铮,沈志浩,任刚.PAF方案在口腔鳞癌术前诱导化疗中的疗效评价[J].口腔颌面外科杂志,2006,16(2):118-120. 被引量:7
  • 4吴芳,张弘纲.多西紫杉醇在晚期胃癌的临床应用[J].癌症进展,2007,5(3):276-281. 被引量:42
  • 5Eich HT, L~schcke M, Scheer M, et al. Neoadjuvant radiochemo- therapy and radical resection for advanced squamous cell carcino- ma of the oral cavity, outcome of 134 patients [ J ]. Strahlenther Onkol,2008,184 ( 1 ) : 23 - 29.
  • 6Denis F, Garaud P, Bardet E, et al. Final results of the 94 -01 French Head and Neck Oncology and Radiotherapy Group random-ized trial comparingradiotherapy alone with concomi-tant radioche- motherapy in advanced-stage oropharynx carcinoma [ J ]. J Clin On- col, 2004,22 ( 1 ) :69 - 76.
  • 7Bootz F. Neoadjuvant radiochemotherapy for squamous cell carcino- ma of the oral cavity[J]. HN0,2008,56(2) :183 - 184.
  • 8Rogers SN, Brown JS, Woolgar JA, et al. Survival following primary surgery for oral cancer[ J ]. Oral Oneo1,2009,45 ( 3 ) :201 - 211.
  • 9Chang PM, Chen PM, Chu PY, et al. Effectiveness of pharmacoki- netic modulating chemotherapy combined with cisplatin as induc- tion chemotherapy in resectable locally advanced head and neck cancer: phase Ⅱ study [ J ]. Cancer Chemother Pharmacol, 2008, 63(1) :9 - 17.
  • 10Van Houten VM ,Leemans CR,Kummer JA,et al. Molecular diag- nosis of surgical margins and local recurrence in head and neck cancer patients : a prospective study [J]. Clin Cancer Res,2004, 10(11) :3614 - 3620.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部